JP2025510911A5 - - Google Patents
Info
- Publication number
- JP2025510911A5 JP2025510911A5 JP2024557189A JP2024557189A JP2025510911A5 JP 2025510911 A5 JP2025510911 A5 JP 2025510911A5 JP 2024557189 A JP2024557189 A JP 2024557189A JP 2024557189 A JP2024557189 A JP 2024557189A JP 2025510911 A5 JP2025510911 A5 JP 2025510911A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- dmt
- meo
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22000083.0 | 2022-03-27 | ||
| EP22000086 | 2022-03-27 | ||
| EP22000086.3 | 2022-03-27 | ||
| EP22000083 | 2022-03-27 | ||
| EP23153995.8 | 2023-01-30 | ||
| EP23153939 | 2023-01-30 | ||
| EP23153995 | 2023-01-30 | ||
| EP23153939.6 | 2023-01-30 | ||
| PCT/EP2023/057883 WO2023186835A1 (en) | 2022-03-27 | 2023-03-27 | Treatment of mental disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025510911A JP2025510911A (ja) | 2025-04-15 |
| JP2025510911A5 true JP2025510911A5 (enExample) | 2026-04-08 |
Family
ID=93292079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024557189A Pending JP2025510911A (ja) | 2022-03-27 | 2023-03-27 | 精神障害の治療 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250241894A1 (enExample) |
| EP (1) | EP4499086A1 (enExample) |
| JP (1) | JP2025510911A (enExample) |
| KR (1) | KR20250005172A (enExample) |
| AU (1) | AU2023246680A1 (enExample) |
| CA (1) | CA3255635A1 (enExample) |
| IL (1) | IL315890A (enExample) |
-
2023
- 2023-03-27 US US18/850,394 patent/US20250241894A1/en active Pending
- 2023-03-27 JP JP2024557189A patent/JP2025510911A/ja active Pending
- 2023-03-27 EP EP23717047.7A patent/EP4499086A1/en active Pending
- 2023-03-27 CA CA3255635A patent/CA3255635A1/en active Pending
- 2023-03-27 IL IL315890A patent/IL315890A/en unknown
- 2023-03-27 AU AU2023246680A patent/AU2023246680A1/en active Pending
- 2023-03-27 KR KR1020247035656A patent/KR20250005172A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025510914A5 (enExample) | ||
| JP2025511081A5 (enExample) | ||
| JP2025511084A5 (enExample) | ||
| JP2025510912A5 (enExample) | ||
| JP2025510916A5 (enExample) | ||
| JP2025510369A5 (enExample) | ||
| JP2025510295A5 (enExample) | ||
| JP2025512831A5 (enExample) | ||
| JP2025510913A5 (enExample) | ||
| CA3255629A1 (en) | 5-METHOXY-N,N-DIMETHYLTRYPTAMINE FOR THE TREATMENT OF SOCIAL/EMOTIONAL WITHDRAWAL OR DETACHMENT | |
| Sinha et al. | Immediate respiratory management of the preterm infant | |
| Sălcudean et al. | The efficacy of antidepresive treatment on COVID-19 pandemic-related depressive symptoms-A prospective, single-center, questionnaire-based study | |
| Bassetti et al. | Poststroke hypersomnia | |
| JP2025510911A5 (enExample) | ||
| MX2007001822A (es) | Uso de xenon como neuroprotector en un individuo neonatal. | |
| Hussein Sr et al. | Anxiolytic and sedative properties of melatonin premedication in pediatrics undergoing elective cardiac catheterization: a randomized placebo study | |
| CN104173363A (zh) | 一种腺苷化合物在制备防治应激障碍药物中的用途 | |
| JP2019504040A (ja) | 中等度〜重度のインフルエンザの処置 | |
| Pasternak et al. | An infant with chronic, relapsing polyneuropathy responsive to steroids | |
| Lamas-Aguilar et al. | Armodafinil as a Potential Pharmacological Treatment for Attention Deficit Hyperactivity Disorder in Adults: A Review | |
| Mogavero et al. | Psychophysiology of Sleep | |
| JP2025511072A5 (enExample) | ||
| Cummins et al. | Belladonna poisoning as a facet of psychodelia | |
| Bozorgipour | COVID-19 infection, Implications, Complications, and Challenges | |
| Kamal | Link of COVID-19 and neurodegenerative disorders |